Document Detail


Rapid enzyme release from acutely infarcted myocardium after early thrombolytic therapy: washout or reperfusion damage?
MedLine Citation:
PMID:  3354399     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a randomized study on early intracoronary thrombolytic therapy in patients with acute myocardial infarction (AMI), serial plasma enzyme activities were measured to analyze the rate of enzyme appearance in plasma with reference to treatment allocation, area at risk, and infarct size. Cumulative activities of alpha-hydroxybutyrate dehydrogenase (HBDH) appearing in plasma in the first 24 hours (Q24), 48 hours (Q48), and 72 hours (Q72) were calculated to obtain infarct size (= Q72) and rate of HBDH appearance in plasma (= Q24/Q72). Analyzed on the basis of "intention to treat" in 448 patients with AMI, the mean Q24/Q72 value (+/- SEM) was 0.653 +/- 0.011 in 230 patients receiving thrombolytic therapy; this value was significantly (p less than 0.001) higher than that observed in 218 patients receiving conventional therapy (0.504 +/- 0.012). In the thrombolysis group Q24/Q72 was independent of infarct size, whereas in the control group Q24/Q72 was negatively correlated with infarct size (r = -0.26; p less than 0.001). Plotted against the sum of ST segment elevations at admission (sigma ST) mean Q24 values were similar in both treatment groups, but mean Q48 and especially Q72 values were larger in the control group than in the thrombolysis group. We conclude that: (1) in reperfused infarctions the time course for development of infarct is accelerated in comparison to unreperfused infarcts; (2) this accelerated process of necrosis lasts about 40 to 50 hours, a duration that is hardly influenced by infarct size; and (3) the reperfusion-induced acceleration of enzyme release resembles the reoxygenation-induced enzyme release from anoxic hearts.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
A van der Laarse; E E van der Wall; R C van den Pol; F Vermeer; F W Verheugt; X H Krauss; F W Bär; W T Hermens; G M Willems; M L Simoons
Related Documents :
2916879 - Feasibility and safety of emergency interhospital transport of patients during early ho...
8034869 - Eligibility for and benefit of thrombolytic therapy in inferior myocardial infarction: ...
11348049 - Repeated thermal therapy upregulates arterial endothelial nitric oxide synthase express...
3095269 - Streptokinase and tissue plasminogen activator in acute myocardial infarction.
3140769 - Intracerebral hemorrhage complicating intravenous tissue plasminogen activator treatment.
2061979 - Selection bias in the use of thrombolytic therapy in acute myocardial infarction. the s...
8640989 - Pure beta-particle-emitting stents inhibit neointima formation in rabbits.
475299 - Sudden postoperative death due to coronary thromboembolus.
15728079 - Cardiac arrest during neuraxial anesthesia: frequency and predisposing factors associat...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American heart journal     Volume:  115     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  1988 Apr 
Date Detail:
Created Date:  1988-05-02     Completed Date:  1988-05-02     Revised Date:  2006-02-27    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  711-6     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, University Hospital Leiden, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Coronary Circulation*
Humans
Hydroxybutyrate Dehydrogenase / blood
Myocardial Infarction / drug therapy,  enzymology*
Random Allocation
Streptokinase / therapeutic use
Time Factors
Chemical
Reg. No./Substance:
EC 1.1.1.-/2-hydroxybutyrate dehydrogenase; EC 1.1.1.30/Hydroxybutyrate Dehydrogenase; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The clinical diagnostic significance of serum antichondrocyte membrane antibodies in osteoarthritis.
Next Document:  Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intrave...